Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Radiotherapy and Oncology is a leading peer-reviewed journal published by Elsevier Ireland Ltd, focusing on the vital fields of hematology, oncology, and radiology. With an impressive impact factor and ranking in the top quartiles (Q1) of its categories as of 2023, it is recognized for disseminating high-quality research that contributes significantly to advancements in cancer treatment and patient care. The journal, which has been in circulation since 1983, aims to provide a platform for original research articles, reviews, and clinical studies that explore the latest innovations in radiotherapeutic technologies and oncology practices. This journal is essential for researchers, healthcare professionals, and students who are dedicated to improving cancer therapies and outcomes. Although it does not offer open access, the wealth of information contained within its pages supports continued education and development in these crucial medical fields.

JACC-Clinical Electrophysiology, published by Elsevier, stands as a leading journal in the fields of Cardiology and Physiology, with an esteemed Q1 ranking in both categories as of 2023. With an ISSN of 2405-500X and E-ISSN 2405-5018, this journal serves as an essential platform for disseminating cutting-edge research, clinical studies, and innovative practices related to electrophysiological aspects of cardiovascular health. Established in 2015, JACC-Clinical Electrophysiology has attracted high-quality submissions, reflected in its strong presence on Scopus, ranking 41st out of 387 in Cardiology and 15th out of 113 in Physiology (medical), placing it in the 89th and 87th percentiles respectively. Though it operates on a subscription model, its commitment to high standards of peer-reviewed scholarship makes it an indispensable resource for researchers, clinicians, and students dedicated to advancing knowledge and practice in electrophysiology and its impact on cardiac care. Join the community of leaders in the field by engaging with the latest findings and discussions published in this prestigious journal.

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

PHLEBOLOGY is a renowned academic journal published by SAGE Publications Inc. that focuses on the evolving field of phlebology and related cardiovascular issues. With an ISSN of 0268-3555 and an E-ISSN of 1758-1125, this journal serves as a pivotal platform for disseminating high-quality research, clinical findings, and innovative practices in venous disease management and treatment. Operating from the United Kingdom, tasked with a mission to advance the scientific understanding and clinical practice surrounding venous disorders, PHLEBOLOGY is currently ranked in the Q3 category for both Cardiology and Cardiovascular Medicine, as well as in Medicine (miscellaneous) for 2023. Its Scopus rank of #192 out of 387 highlights its commitment to excellence, ensuring that it reaches a respectable 50th percentile within its fields. Although it does not offer open access, the journal invites contributions from researchers, healthcare professionals, and students, fostering a community dedicated to improving patient outcomes and promoting evidence-based practices in venous health.

Indian Journal of Gynecologic Oncology, published by SPRINGER INDIA, is a distinguished platform dedicated to the rigorous dissemination of research and advancements in the fields of gynecologic oncology. With an ISSN of 2363-8397 and E-ISSN of 2363-8400, the journal aims to bridge the gap between clinical practice and research in obstetrics and gynecology, while also addressing pivotal issues in oncology. Operating from its headquarters in New Delhi, India, the journal has been active since 2016 and is recognized within the academic community, achieving a Category Quartile of Q3 in Obstetrics and Gynecology and Q4 in Oncology as of 2023. Although currently not an open-access journal, it offers extensive access options for subscribing institutions and professionals. With its commitment to high-quality peer-reviewed content, the journal serves as a vital resource for researchers, clinicians, and students dedicated to advancing knowledge and improving patient outcomes in gynecologic cancers.

Photodiagnosis and Photodynamic Therapy is a leading journal published by Elsevier, specializing in the fields of biophysics, dermatology, oncology, and pharmacology. With an impressive Q2 ranking across multiple categories in the 2023 category quartiles, this journal is pivotal for researchers and practitioners aiming to advance their knowledge and expertise in photodiagnostic and therapeutic techniques. Since its inception in 2004, it has provided a critical platform for peer-reviewed articles exploring the latest advancements and applications in light-based treatments. As of 2024, the journal will be fully Open Access, enhancing its accessibility and reach across the scientific community. Located in Amsterdam, Netherlands, this journal's commitment to fostering innovation and collaboration makes it an essential resource for those interested in the intersection of light-based technologies and medicine. With its high visibility in key indexed databases like Scopus, researchers can trust that their contributions will be well-regarded and widely disseminated.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

Molecular Imaging and Radionuclide Therapy is an esteemed academic journal published by GALENOS PUBL HOUSE, dedicated to advancing the fields of radiology, nuclear medicine, and imaging. Since its inception, this Open Access journal has facilitated the dissemination of high-quality research and innovative practices in molecular imaging and radionuclide therapy, making it a vital resource for researchers, professionals, and students alike. With an ISSN of 2146-1414 and an E-ISSN of 2147-1959, the journal has established its presence globally while specifically catering to the Turkish academic and medical community. As of 2023, it is ranked #241/333 in the Radiology, Nuclear Medicine and Imaging category on Scopus, holding a respectable Q3 quartile ranking. The journal serves as a platform for sharing impactful findings from 2017 to 2024, reinforcing its commitment to open access since 2011. With a dedication to enhancing the knowledge base in molecular imaging and therapy, it remains an important conduit for scholarly communication and collaborative research developments in this dynamic field.